samedan logo
 
 
spacer
home > epc > summer 2007 > maximise your monitor
PUBLICATIONS
European Pharmaceutical Contractor

Maximise Your Monitor

How can well-trained field clinical research monitors be optimised to become a real asset to study sites and trial sponsors? Pfizer’s Anick Duchesne offers her vision

Learning how to ‘think outside of the box’ and explore the ways in which the role of well-trained and motivated field clinical research monitors could be optimised is by no mean simple. However, this process allows such professionals to break out of the standardised and self-limiting ‘core monitoring routine’ and grow into an expanded business resource to the benefit of aspiring and participating study sites and sponsoring organisations.

This article will initially present a broad outline of this role enhancement concept, as well as a business/operational rationale for its development and successful implementation within industry. A follow-up article will examine in greater detail what are perceived to be potential benefits, as well as inherent challenges, of the successful leveraging of the expanded business role of field monitors in our pharmaceutical clinical research environment.

THE ROLE OF A FIELD MONITOR

The field monitor is responsible for influencing study site personnel through an effective collaborative working relationship to achieve peak performance in all inter-related spheres of clinical research business activity. It should be noted that while some of the concepts about to be explored may work to some degree within a project-based model, this definition is really meant to be applied to a regionally-based monitoring organisation.

Also, many of these concepts assume an already established monitoring group. Whilst part of this definition has been used in defining the roles of senior clinical research associates and some site managers, it is believed that the full breadth intended is rarely put into practice. I wish to dissect the intentions of the role and highlight that it is more than a mere title change or a few added responsibilities.

Business Partners
With this definition, the monitor must be able to develop and grow business partnerships. Hence, one must be able to assess site performance from an organisational business perspective, to diagnose problems with efficiency and effectiveness and to assist sites at resolving misalignments or identified gaps. The monitor would participate as a business partner in developing and implementing a solid business plan. Needless to say, individuals fulfilling this enhanced role must possess the necessary skills to develop and enhance a business partnership over time.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As a senior leader of the Clinical Research Department at Pfizer Canada, Anick Duchesne is responsible for the site management and monitoring, research operations, biometrics and data management, and pharmacy services teams. In her time at Pfizer, Anick established a regional monitoring organisation and designed flexible organisations with CRO partnerships and strategic monitoring acceleration response team members.
spacer
Anick Duchesne
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Vindon Scientific on the Move

 
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement